AgomAb Therapeutics NV’s Lock-Up Period To End on August 5th (NASDAQ:AGMB)

Posted by Trevor Kearing on Jul 30th, 2026

AgomAb Therapeutics’ (NASDAQ:AGMB – Get Free Report) lock-up period will expire on Wednesday, August 5th. AgomAb Therapeutics had issued 12,500,000 shares in its initial public offering on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. After the end of AgomAb Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analyst Weigh In

Several research firms have commented on AGMB. HC Wainwright started coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. B. Riley Financial began coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Read Our Latest Stock Analysis on AgomAb Therapeutics

AgomAb Therapeutics Trading Up 2.9%

Shares of NASDAQ:AGMB opened at $12.76 on Friday. The stock has a 50-day simple moving average of $11.94. AgomAb Therapeutics has a 12-month low of $8.75 and a 12-month high of $17.82.

About AgomAb Therapeutics

(Get Free Report)

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.